← 治験一覧に戻る
重度の尋常性乾癬を患う小児および青年を対象とした小児臨床試験
基本情報
- NCT ID
- NCT02471144
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 162
- 治験依頼者名
- Novartis
概要
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to \<18 years were enrolled, of which at least 30 were 6 years to \<12 years old. Subjects were enrolled at approximately 70 study sites worldwide.
対象疾患
Chronic Severe Plaque-type Psoriasis
介入
Experimental : Secukinumab low dose(BIOLOGICAL)
Experimental: Secukinumab high dose(BIOLOGICAL)
Placebo Comparator: Secukinumab Placebo(BIOLOGICAL)
Active Comparator: Etanercept(BIOLOGICAL)
依頼者（Sponsor）
ノバルティスファーマ株式会社(INDUSTRY)